Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 25, 2003
Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseasesRichard A Nash, Roger Dansey, Jan Storek, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 2, 2011
Development and validation of a test dose strategy for once-daily i.v. busulfan: importance of fixed infusion rate dosingS Bill Kangarloo, Farrukh Naveed, Ella S M Ng, et al.
Blood|August 15, 2002
High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomesPeter A McSweeney, Richard A Nash, Keith M Sullivan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 19, 2012
Transplantation for autoimmune diseases in north and South America: a report of the Center for International Blood and Marrow Transplant ResearchMarcelo C Pasquini, Julio Voltarelli, Harold L Atkins, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 23, 2019
Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow TransplantationJeffrey A Cohen, Laura E Baldassari, Harold L Atkins, et al.
Blood|May 24, 2003
High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosisRichard A Nash, James D Bowen, Peter A McSweeney, et al.
Blood|October 30, 2010
Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myelomaAaron P Rapoport, Nicole A Aqui, Edward A Stadtmauer, et al.
Rheumatology (Oxford, England)|February 2, 2022
Lymphocyte subset abnormalities in early severe scleroderma favor a Th2 phenotype and are not altered by prior immunosuppressive therapyAnkoor Shah, Jan Storek, Rob Woolson, et al.
Blood|March 30, 2016
Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cellsAmina Kariminia, Shernan G Holtan, Sabine Ivison, et al.
The Journal of Rheumatology|February 19, 2013
Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trialEmily W Hung, Maureen D Mayes, Roozbeh Sharif, et al.
Pageof 12